These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3144531)

  • 1. Therapeutic effect of fleroxacin against experimental pneumonia in mice.
    Niki Y; Watanabe M; Tasaka Y; Umeki S; Soejima R
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():129-31. PubMed ID: 3144531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice.
    Obana Y; Nishino T
    Drugs Exp Clin Res; 1989; 15(2):53-8. PubMed ID: 2661182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapeutic effects of ofloxacin (HOE 280) and other quinolone-carboxylic derivates in the treatment of experimental lung infections due to Klebsiella pneumoniae DT-S in mice.
    Klesel N; Limbert M; Seibert G; Winkler I; Schrinner E
    Infection; 1986; 14 Suppl 1():S36-9. PubMed ID: 2937738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative activities of norfloxacin and fleroxacin in experimental infections due to Salmonella typhimurium and Escherichia coli.
    Hof H; Fabrig J
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():123-7. PubMed ID: 3144530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo evaluation of a dual-action antibacterial, Ro 23-9424, compared to cefotaxime and fleroxacin.
    Beskid G; Siebelist J; McGarry CM; Cleeland R; Chan K; Keith DD
    Chemotherapy; 1990; 36(2):109-16. PubMed ID: 2107064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro and in-vivo antibacterial activity of fleroxacin, a new fluorinated quinolone.
    Aoyama H; Inoue M; Mitsuhashi S
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():99-114. PubMed ID: 2849604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro activity of fleroxacin.
    Georgopoulos A; Breyer S; Georgopoulos M; Mailer H; Graninger W
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():25-9. PubMed ID: 3144544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative studies of fleroxacin and ofloxacin in experimental pyelonephritis.
    Ritzerfeld W
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():119-22. PubMed ID: 3144529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro studies of fleroxacin (Ro 23-6240), a new trifluorinated quinolone derivative.
    Digranes A; Benonisen E; Salveson A; Zahm F
    Chemotherapy; 1988; 34(5):401-10. PubMed ID: 3141116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of fleroxacin compared with three other quinolones.
    Bremner DA; Dickie AS; Singh KP
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():19-23. PubMed ID: 3144536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.
    Bakker-Woudenberg IA; ten Kate MT; Guo L; Working P; Mouton JW
    Antimicrob Agents Chemother; 2001 May; 45(5):1487-92. PubMed ID: 11302815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.
    Rodríguez-Martínez JM; Pichardo C; García I; Pachón-Ibañez ME; Docobo-Pérez F; Pascual A; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2008 Jul; 14(7):691-7. PubMed ID: 18558942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo activity of antifungal agents in combination with fleroxacin, a new quinolone.
    Polak A
    Mycoses; 1990 Apr; 33(4):173-8. PubMed ID: 2122247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of amikacin, ofloxacin, pefloxacin, ciprofloxacin, enoxacin and fleroxacin in experimental left-sided Pseudomonas aeruginosa endocarditis.
    Papadakis JA; Samonis G; Maraki S; Boutsikakis J; Petrocheilou V; Saroglou G
    Chemotherapy; 2000; 46(2):116-21. PubMed ID: 10671762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in-vitro activity of fleroxacin and other 6-fluoroquinolones against mycobacteria.
    Salfinger M; Hohl P; Kafader FM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():55-63. PubMed ID: 3144550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin.
    Paganoni R; Herzog C; Braunsteiner A; Hohl P
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():3-17. PubMed ID: 3144545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro susceptibility of staphylococci to fleroxacin in comparison with six other quinolones.
    Pohlod DJ; Saravolatz LD; Somerville MM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():35-41. PubMed ID: 3144547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
    Verbist L
    J Antimicrob Chemother; 1987 Sep; 20(3):363-72. PubMed ID: 3119552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of fleroxacin on HeLa cell functions and topoisomerase II.
    Oomori Y; Yasue T; Aoyama H; Hirai K; Suzue S; Yokota T
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():91-7. PubMed ID: 2849603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinolone pharmacokinetics and metabolism.
    Lode H; Höffken G; Boeckk M; Deppermann N; Borner K; Koeppe P
    J Antimicrob Chemother; 1990 Oct; 26 Suppl B():41-9. PubMed ID: 2124212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.